Compare KRNY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KRNY | SGMT |
|---|---|---|
| Founded | 1884 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.5M | 676.3M |
| IPO Year | 2014 | 2021 |
| Metric | KRNY | SGMT |
|---|---|---|
| Price | $9.56 | $11.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.25 | ★ $26.13 |
| AVG Volume (30 Days) | 527.5K | ★ 865.8K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,580,000.00 | $2,000,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $16.81 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $6.23 | $4.50 |
| 52 Week High | $10.24 | $11.45 |
| Indicator | KRNY | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 61.34 |
| Support Level | $9.43 | $6.60 |
| Resistance Level | $9.74 | $11.30 |
| Average True Range (ATR) | 0.21 | 0.55 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 12.66 | 77.98 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.